Identification of Dominant Optic Atrophy Following Reanalysis of Clinical Exome Sequencing

Overview

Journal Am J Ophthalmol Case Rep

Specialty Ophthalmology

Date 2023 Mar 28

PMID 36974169

Authors

Michael C Brodsky

Rory J Olson

Faizal Z Asumda

Madeline Q R Lopour

Lisa A Schimmenti

Eric W Klee

Affiliations

Soon will be listed here.

Abstract

Purpose: To highlight the importance of the utility of clinical exome sequencing, and show how it led to the diagnosis of nonsyndromic autosomal dominant optic atrophy arising from an autosomal dominant variant in

Observations: A healthy father and daughter of East African heritage experienced the onset of vision loss in the first decade of life due to optic atrophy. No additional neurologic or neuroimaging abnormalities were detected. Clinical exome sequencing was initially performed and provided a negative result. Reanalysis of the sequencing data revealed an autosomal dominant pathogenic variant in , c.1064C>T (p.Thr355Met), a gene that was recently identified to be associated with non-syndromic optic atrophy. This variant has previously been reported in a patient with optic atrophy, motor disturbances, and an abnormal brain MRI.

Conclusions: As the causes of dominant optic atrophy continue to expand, accurate genetic diagnosis is aided by an iterative reanalysis process for individuals and families when initial exome and genome testing does not provide an answer.

References

Colavito D, Maritan V, Suppiej A, Del Giudice E, Mazzarolo M, Miotto S . Non-syndromic isolated dominant optic atrophy caused by the p.R468C mutation in the AFG3 like matrix AAA peptidase subunit 2 gene. Biomed Rep. 2017; 7(5):451-454. PMC: 5700392. DOI: 10.3892/br.2017.987. View

Votruba M, Leary S, Losseff N, Bhattacharya S, Moore A, Miller D . MRI of the intraorbital optic nerve in patients with autosomal dominant optic atrophy. Neuroradiology. 2000; 42(3):180-3. DOI: 10.1007/s002340050041. View

Thiselton D, Alexander C, Taanman J, Brooks S, Rosenberg T, Eiberg H . A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2002; 43(6):1715-24. View

Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P . Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003; 278(10):7743-6. DOI: 10.1074/jbc.C200677200. View

Votruba M, Fitzke F, Holder G, Carter A, Bhattacharya S, Moore A . Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol. 1998; 116(3):351-8. DOI: 10.1001/archopht.116.3.351. View

Alexander C, Votruba M, Pesch U, Thiselton D, Mayer S, Moore A . OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000; 26(2):211-5. DOI: 10.1038/79944. View

Meire F, De Laey J, de Bie S, Van Staey M, Matton M . Dominant optic nerve atrophy with progressive hearing loss and chronic progressive external ophthalmoplegia (CPEO). Ophthalmic Paediatr Genet. 1985; 5(1-2):91-7. DOI: 10.3109/13816818509007861. View

Klee E, Cousin M, Pinto E Vairo F, Morales-Rosado J, Macke E, Jenkinson W . Impact of integrated translational research on clinical exome sequencing. Genet Med. 2020; 23(3):498-507. DOI: 10.1038/s41436-020-01005-9. View

Charif M, Roubertie A, Salime S, Mamouni S, Goizet C, Hamel C . A novel mutation of AFG3L2 might cause dominant optic atrophy in patients with mild intellectual disability. Front Genet. 2015; 6:311. PMC: 4609881. DOI: 10.3389/fgene.2015.00311. View

10.

Bella D, Lazzaro F, Brusco A, Plumari M, Battaglia G, Pastore A . Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet. 2010; 42(4):313-21. DOI: 10.1038/ng.544. View

11.

Magri S, Fracasso V, Plumari M, Alfei E, Ghezzi D, Gellera C . Concurrent AFG3L2 and SPG7 mutations associated with syndromic parkinsonism and optic atrophy with aberrant OPA1 processing and mitochondrial network fragmentation. Hum Mutat. 2018; 39(12):2060-2071. DOI: 10.1002/humu.23658. View

12.

Koppen M, Langer T . Protein degradation within mitochondria: versatile activities of AAA proteases and other peptidases. Crit Rev Biochem Mol Biol. 2007; 42(3):221-42. DOI: 10.1080/10409230701380452. View

13.

Hudson G, Amati-Bonneau P, Blakely E, Stewart J, He L, Schaefer A . Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain. 2007; 131(Pt 2):329-37. DOI: 10.1093/brain/awm272. View

14.

KJER P . Hereditary infantile optic atrophy with dominant transmission; preliminary report. Dan Med Bull. 1956; 3(5):135-41. View

15.

Delettre C, Lenaers G, Griffoin J, Gigarel N, Lorenzo C, Belenguer P . Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000; 26(2):207-10. DOI: 10.1038/79936. View

16.

Yu-Wai-Man P, Griffiths P, Gorman G, Lourenco C, Wright A, Auer-Grumbach M . Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010; 133(Pt 3):771-86. PMC: 2842512. DOI: 10.1093/brain/awq007. View

17.

Hoyt C . Autosomal dominant optic atrophy. A spectrum of disability. Ophthalmology. 1980; 87(3):245-51. DOI: 10.1016/s0161-6420(80)35247-0. View

18.

KLINE L, Glaser J . Dominant optic atrophy. The clinical profile. Arch Ophthalmol. 1979; 97(9):1680-6. DOI: 10.1001/archopht.1979.01020020248013. View

19.

Nolden M, Ehses S, Koppen M, Bernacchia A, Rugarli E, Langer T . The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. Cell. 2005; 123(2):277-89. DOI: 10.1016/j.cell.2005.08.003. View

20.

Carelli V, Ross-Cisneros F, Sadun A . Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004; 23(1):53-89. DOI: 10.1016/j.preteyeres.2003.10.003. View